SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: VLAD who wrote (6590)5/10/1999 4:07:00 PM
From: biodoc  Read Replies (2) of 7041
 
I too just finished the cc. The approach is to try to spin a non-approvable letter into a marketing decision to submit more data and get a better label a year later. This is just crap. The drug couldn't be approved with the data they have and they know it.

Also, some wording in a description of the 69% efficacy open label trial suggested that it was 69% efficacious in men who stayed on the drug long term. -- Well, it would be very important to know how many men DIDN't stay on long term in that trial because it didn't work or because of side effects. In other words, is the 69% figure an intent-to-treat result, or is it the result in a population enriched with responders (no pun intended).

I bought my puts and will buy more if there is a bounce.

Biodoc
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News